Physician profile
Natesh Lingam
NPI 1801005145
$5,288.20
in general payments reported to CMS, 2019-2025
41 companies · $652 in 2025
The $652 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $829 · 2020: $156 · 2021: $512 · 2022: $977 · 2023: $968 · 2024: $1,194 · 2025: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,813.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $702.98 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $520.53 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $513.51 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $389.38 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $374.76 | 2019-2024 | Xarelto |
| Pfizer INC. | $347.18 | 2019-2025 | |
| Heartflow, INC. | $308.61 | 2024-2025 | |
| Shockwave Medical, INC | $279.17 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.47 | 2022-2025 | Jardiance, Stiolto Respimat |
| Abbott Laboratories | $152.73 | 2020-2025 | Xience Skypoint, Cardiomems, Diamondback Coronary |
| Philips North America LLC | $150.57 | 2022-2025 | Diagnostic Ecg Service |
| Merck Sharp & Dohme LLC | $138.06 | 2022-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Penumbra, INC. | $113.90 | 2023 | Indigo System |
| Regeneron Healthcare Solutions, INC. | $111.14 | 2019-2021 | |
| Edwards Lifesciences Corporation | $107.58 | 2019-2021 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $87.57 | 2020-2023 | Opsumit |
| Chiesi USA, INC. | $82.72 | 2022-2025 | Kengreal |
| Kiniksa Pharmaceuticals International, Plc | $74.41 | 2024 | Arcalyst |
| Boston Scientific Corporation | $73.00 | 2021-2023 | Watchman Flx, Wolverine Coronary Cutting Balloon, Ekosonic |
| Astrazeneca Pharmaceuticals LP | $72.71 | 2019-2025 | Brilinta |
| Siemens Medical Solutions USA, INC. | $50.77 | 2019 | |
| Dexcom, INC. | $47.43 | 2023-2024 | Dexcom G6 Transmitter |
| Nestle Healthcare Nutrition INC. | $40.41 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $38.67 | 2019 | |
| Vifor Pharma, INC. | $36.86 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $29.46 | 2023 | Arcalyst |
| Janssen Biotech, INC. | $27.63 | 2025 | Tremfya |
| Amarin Pharma, INC. | $24.75 | 2019 | |
| Daiichi Sankyo INC. | $23.40 | 2023 | Injectafer |
| Braemar Manufacturing, LLC | $22.44 | 2019 | |
| Exact Sciences Corporation | $20.66 | 2025 | Cologuard Collection Kit |
| Irhythm Technologies, INC. | $20.23 | 2023 | Zio Xt Patch |
| Lexicon Pharmaceuticals, INC. | $19.43 | 2023 | Inpefa |
| Abiomed | $18.63 | 2025 | |
| Teleflex LLC | $16.28 | 2024 | Guideliner |
| Novo Nordisk INC | $16.17 | 2023 | Wegovy |
| Scpharmaceuticals INC. | $15.89 | 2024 | |
| Medtronic, INC. | $15.55 | 2022 | |
| Electromed, INC. | $13.93 | 2022 | |
| Medicomp INC | $13.36 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.27 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natesh Lingam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.